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Background:The left ventricular hypertrophy (LVH) occurs in response to the hae-
modynamic overload in some physiological and pathological conditions. This study 
was designed to investigate the possible cardioprotective effect of simvastatin (SIM) 
treatment against isoproterenol (ISO)-induced LVH and the probable underlying 
mechanism in adult male Wistar rats. 
Materials and methods: Animals were allocated into four groups. Rats of con-
trol group received normal saline orally for 30 days and intraperitoneally for the 
last 7 days. Rats of SIM group received SIM orally (10 mg/kg/day in saline) for 
30 days. Rats of ISO group received normal saline orally for 30 days and ISO 
intraperitoneally (5 mg/kg) for the last 7 days to induce LVH. Rats of ISO/SIM 
group received SIM for 30 days and ISO intraperitoneally for the last 7 days. At 
the end of the experiment, all animals were sacrificed by cervical decapitation 
under anaesthesia. Truncal blood was collected and serum was separated and 
used for biochemical assay. The heart was dissected and processed for histological 
and immunohistochemical studies.
Results: The results of the present study confirmed the ISO-induced myocardial 
lesions including significant increase of heart weight (HW), heart weight/body 
weight (HW/BW) ratio, LVH, interstitial myocardial fibrosis (increased collagen 
types I and III), inflammatory cellular infiltration, necrosis of cardiomyocytes, and 
increased expression of inducible nitric oxide synthase (iNOS) and thioredoxin 
in cardiomyocytes. These changes were accompanied by significant increase 
in serum levels of troponin-T, creatine phosphokinase-MB (CPK-MB), tumour 
necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6). Co-administration of SIM 
to ISO-injected rats significantly reduced all these cardiac changes and serum 
biochemical markers in addition to marked depletion of iNOS and thioredoxin 
expression in cardiomyocytes. 
Conclusions: It is concluded that SIM co-administration attenuated ISO-induced 
cardiac lesions including LVH by inhibiting iNOS expression in cardiomyocytes. 
(Folia Morphol 2017; 76, 1: 15–27)
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INtrOductION
Hypertension is one of the main causes of left ven-
tricular cardiac hypertrophy (LVH) that is considered 
as the major risk factor for heart failure [16, 32, 56]. 
The key pathological processes in LVH include hyper-
trophy of the cardiomyocytes and fibrosis of the myo-
cardial interstitium [24]. Failure of the hypertrophied 
heart involves a complex sequence of events at the 
molecular and cellular levels including alteration in 
the metabolism of extracellular matrix collagen [40]. 
Porter and Turner [40] reported that extracellular ma-
trix collagen plays an essential role in maintaining the 
architecture and preserving the contractile function 
of the myocardium. It was found that a large amount 
of collagen is secreted into the intercellular spaces of 
the myocardium during the process of LVH [21]. This 
contributes to myocardial stiffness and ventricular 
dysfunction [50]. It was hypothesized that enhance-
ment of myocardial fibrosis secondary to increased 
collagen types I and III synthesis and deposition leads 
to development of heart failure in cases with hyper-
tensive heart disease [24, 41].
Inducible nitric oxide synthase (iNOS) is normally 
expressed at a low level in cardiomyocytes [44]. Sev-
eral investigators have demonstrated that iNOS ex-
pression in cardiomyocytes is increased by numerous 
stimuli including inflammatory mediators, cytokines, 
tissue ischaemia, hypertension, and LVH [19, 31, 
38, 44]. Overexpression of iNOS in cardiomyocytes 
increased myocardial nitric oxide (NO) production 
and resulted in inflammatory cell infiltrate, LVH, car-
diac fibrosis and contractile dysfunction. Moreover, 
iNOS deficiency (iNOS–/–) attenuates LVH and iNOS 
expressed in response to systolic overload serves as 
a source for myocardial reactive oxygen species (ROS) 
that contribute to LVH [61].
Induction of iNOS produces excessive amounts of 
NO, which reacts with superoxide (O2
–) to form the 
high cytotoxic oxidant peroxynitrite. Also, iNOS itself 
is capable to produce O2
–, which is transformed to 
hydrogen peroxide [13, 23, 59]. Both peroxynitrite 
and hydrogen peroxide induced tissue injury and 
organ dysfunction including the heart [18, 23, 36].
Oxidative stress produced by ROS is known to 
regulate collagen metabolism in cardiac fibroblasts, 
which are the major cell type responsible for collagen 
synthesis and degradation in the myocardium [46]. In 
addition, ROS may be involved in triggering inflamma-
tory reactions through the induction of cytokines [29]. 
Previous investigations [7, 43] have demonstrated that 
repeated daily injection of isoproterenol (ISO) induces 
substantial LVH, necrosis, and fibrosis. These changes 
are attributed to an increase in myocardial oxidative 
stress as a result of the formation of the highly cyto-
toxic oxidant peroxynitrite [39]. Also, experimental 
data suggest that the release of O2
– induces cardiac 
myocyte hypertrophy [51]. Inhibiting LVH has emerged 
as a primary target for therapeutic approaches in pre-
venting hypertension-induced end-organ damage [35].
Statins, hydroxymethylglutaryl-coenzyme A reduc-
tase inhibitors, are widely prescribed cholesterol-low-
ering agents that decrease the incidence of myocar-
dial infarction and ischaemic stroke [26]. Simvastatin 
(SIM), a member of statins, has been recognised to 
have antioxidant effects and is an effective agent for 
preventing the development of cardiac hypertrophy 
(through an antioxidant mechanism) [51]. Hence, the 
present study was designed to investigate the pos-
sible anti-hypertrophic activity of SIM pretreatment 
against ISO-induced LVH in rats and to determine the 
potential underlying mechanism involved.
MaterIalS aNd MethOdS
Experimental animals
Twenty-four adult male Wistar albino rats, with 
a body weight (BW) between 160 and 180 g, were 
supplied by the Animal Care Centre at the College of 
Medicine, King Saud University, Riyadh, Kingdom of 
Saudi Arabia. Rats were housed and maintained under 
standard controlled environmental conditions in indi-
vidual plastic cages at a temperature of 25 ± 2°C on 
12-h light/dark cycle throughout the study with free 
access to standard pelleted rat chow and tap water 
ad libitum. The animals were acclimatised for a period 
of 1 week before the start of the experiment. All the 
experimental procedures were conducted according 
to the Guidelines for the Care and Use of Laboratory 
Animals of the College of Medicine Research Centre 
(CMRC) at King Saud University and conform to the 
Guide for the Care and Use of Laboratory Animals 
published by the National Institutes of Health (NIH).
Chemicals
Isoproterenol and simvastatin were purchased 
from Sigma, St. Louis, Mo, USA. Mouse monoclonal 
anti-iNOS (anti-NOS-2) antibody was obtained from 
Santa Cruz Biotechnology (Dallas, TX, USA). Mouse 
monoclonal anti-collagen III antibody and rabbit poly-
clonal anti-thioredoxin were obtained from abcam 
(Cambridge, UK). SIM is one of hydroxymethylglutaryl- 
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-coenzyme A reductase inhibitors. It has antioxidant 
properties [38].
Experimental design
Animals were randomly allocated into four groups 
of 6 rats each:
— Control group: rats received normal saline orally for 
30 days and intraperitoneally for the last 7 days;
— SIM group: rats received SIM (10 mg/kg/day) dis-
solved in saline by oral gavage for 30 days [8];
— ISO group: rats received normal saline orally for 
30 days and ISO (5 mg/kg/day intraperitoneally) 
for the last 7 days [57, 60];
— ISO/SIM group: rats received SIM (10 mg/kg) dis-
solved in saline by oral gavage for 30 days and ISO 
(5 mg/kg/day intraperitoneally) for the last 7 days.
At the end of the experiment, all animals were 
sacrificed by cervical decapitation under anaesthesia 
and truncal blood samples were collected and centri-
fuged to separate sera. Sera were kept at –20°C and 
used for biochemical assays. Hearts were immediately 
excised, fixed in 10% buffered formalin and processed 
for histological and immunohistochemical studies.
Body weight, heart weight, and heart weight/ 
/body weight ratio
At the end of the experiment, BW and heart 
weight (HW) were measured. The HW/BW ratio was 
calculated and used as a sensitive indicator of cardiac 
hypertrophy [15, 58].
Serum biochemical analysis
Determination of serum levels of troponin-T 
and creatine phosphokinase-MB (CPK-MB). Serum 
levels of troponin-T were measured using a Siemens 
Dimension Xpand Plus instrument (IL, USA). Also, 
serum levels of CPK-MB isoenzyme were determined 
with an auto-analyser (ILab-300, bioMérieux Diag-
nostics, Milan, Italy). Both troponin-T and CPK-MB are 
cardiac injury markers. CPK-MB is the bound combina-
tion of two variants (isoenzymes, CPKM and CPKB) of 
the enzyme creatine phosphokinase [17].
Determination of serum levels of tumour necro-
sis factor-alpha (TNF-a). The serum concentration of 
TNF-a (an inflammatory cytokine) was measured using 
enzyme-linked immunosorbent assay (ELISA) kits fol-
lowing the instructions supplied by the manufacturer 
(DuoSet Kits, R&D Systems, Minneapolis, MN, USA).
Determination of serum levels of interleukin-6 
(IL-6). Serum levels of IL-6 were measured by ultra-
sensitive ELISA (Quantikine HS Human IL-6 Immuno- 
assay, R&D Systems, Minneapolis, MN, USA) [25].
Histopathological study
The excised hearts were fixed in 10% buffered for-
malin at 4°C for 24 h and processed to prepare trans-
verse, midventricular, 5-µm-thick paraffin sections. 
These sections were stained with haematoxylin and 
eosin (H&E) [48] and Masson’s trichrome stains [6].
Immunohistochemical study
Immunostaining of the heart sections for detec-
tion of collagen type III, iNOS (NOS-2) and thiore-
doxin were performed using streptavidin-biotinylat-
ed horse radish peroxidase method (Novalink Max 
Polymer detection system; Novocastra Laboratories, 
Newcastle, UK). The procedure involved the follow-
ing steps: endogenous peroxidase activity was inhib-
ited by 3% H2O2 in distilled water for 5 min and then 
the sections were washed in Tris-buffered saline (TBS, 
pH 7.6) (Sigma-Aldrich) for 10 min. Non-specific 
binding to antibodies was blocked by incubation 
with protein block for 5 min (Novocastra). Sections 
were incubated with an antibody against collagen 
III (1:100 dilution, abcam, Cambridge, UK), an an-
tibody against iNOS (NOS-2) (1:100 dilution, Santa 
Cruz, TX, USA) and an antibody against thioredoxin 
(1:200 dilution, abcam, Cambridge, UK) according 
to the manufacturer’s instructions. Sections were 
washed 3 times in TBS, each for 3 min, and then 
incubated with biotinylated IgG (Novocastra) for 
30 min, followed by washing in TBS and incubation 
with Novolink polymer (Novocastra) for 30 min. Sec-
tions were washed in TBS for 3 times, each for 3 min. 
Peroxidase was detected with working solution of 
diaminobenzidine (DAB) substrate (Novocastra) for 
10 min. Sections were washed in distilled water for 
10 min, nuclei were stained with Mayer’s haematoxy-
lin and sections were mounted in DPX (Dysterene, 
Plasticizer, Xylene). For negative control sections, the 
same procedure was followed but with omission of 
incubation in the primary antibodies.
Image analysis
High-resolution whole-slide digital scans of all 
stained sections were created with a ScanScope 
scanner (Aperio Technologies, Inc.). The digital slide 
images were then viewed and analysed using the 
viewing and image analysis tools of Aperio’s Ima-
geScope software (Aperio Technologies, Inc.). To 
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quantify the immunopositive reaction and the extent 
of fibrosis, five areas, each with the fixed size of 
0.264 mm2, were randomly selected per section, and the 
colour deconvolution (colour separation) algorithm 
(Aperio Technologies, Inc.) was set up (by colour cali-
bration) to detect and quantify only the brown colour 
of DAB positive immunostaining or only the green 
colour of fibrous tissue (as stained by Masson’s tri-
chrome). The algorithm was then run on the selected 
areas to measure the percentage of the colour of inter-
est relative to the total area of analysis. The thickness 
of the wall of the left ventricle (LV) was measured on 
the digital scans of H&E-stained slides, using the linear 
measurement tool of Aperio’s ImageScope software 
(Aperio technologies, Inc.). To minimise error, thick-
ness was measured at 5 randomly chosen points per 
heart section and averages were calculated. All image 
analysis output results were finally exported to Excel 
sheets and subjected to statistical analysis.
Statistical analysis
Data collected were subjected to statistical analy-
sis using IBM SPSS Statistics version 22 software. The 
homogeneity of variance was first checked with Lev-
ene test. Analysis of variance (ANOVA) was used for 
an overall comparison between the groups followed 
by Bonferroni test (when the homogeneity of vari-
ance assumption was met) or by Games-Howell test 
(when the homogeneity of variance assumption was 
not met) as post-hoc tests for pairwise comparisons. 
Differences were considered significant when p was 
less than or equal to 0.05.
reSultS
Clinical observations
All rats used in the present study survived till 
the end of the experiment. This indicated that 
intraperitoneal injection of ISO provided a sim-
ple, non-invasive procedure to induce myocar-
dial hypertrophy including LVH with almost no 
incidence of mortality. All animals of ISO group 
demonstrated lethargy and marked reduction of 
movements.
Heart weight and heart weight/body weight ratio 
The results showed significant increase in HW and 
HW/BW ratio in the ISO-injected rats as compared with 
the control rats. Treatment of ISO-injected rats with 
SIM induced significant reduction of both HW and HW/ 
/BW ratio as compared with ISO-injected rats (Table 1).
Left ventricular wall thickness 
Isoproterenol-injected rats exhibited significant in-
crease in LV wall thickness inducing LVH as compared 
with control rats. Treatment of ISO-injected rats with 
SIM induced marked decrease in LV wall thickness as 
compared with ISO-injected rats (Table 2).
Serum biochemical analysis
Serum levels of troponin-T and CPK-MB. ISO-
-injected rats exhibited significant increase in serum 
levels of cardiac injury markers, namely troponin-T 
and CPK-MB, as compared with control rats. Treat-
ment of ISO-injected rats with SIM significantly 
Table 1. Relative heart weight (heart/body weight; mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO/SIM)
Mean ± SEM 0.003 ± 0.000 0.003 ± 0.000 0.006 ± 0.000 0.004 ± 0.000
P1 0.922 0.004* 0.026*
P2 0.922 0.005* 0.001*
P3 0.004* 0.005* 0.010* 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
Table 2. Left ventricular wall thickness (μm; mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO/SIM)
Mean ± SEM 2.436 ± 0.082 2.418 ± 0.091 4.142 ± 0.116 3.202 ± 0.134
P1 1.000 0.000* 0.000*
P2 1.000 0.000* 0.000*
P3 0.000* 0.000* 0.000* 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
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reduced the serum levels of these cardiac injury mark-
ers as compared with ISO-injected rats (Tables 3, 4).
Serum levels of TNF-a and IL-6. Serum levels of pro-
inflammatory biomarkers, namely TNF-a and IL-6, were 
significantly elevated in ISO-injected rats as compared 
with control rats and significantly reduced in ISO/SIM 
rats as compared with ISO-injected rats (Tables 5, 6).
Histopathological study
Haematoxylin and eosin-stained mid-ventricular 
cross sections of the heart from control rats and rats 
treated with SIM alone showed normal microscopic 
features of cardiomyocytes and interstitial connective 
tissue (Fig. 1A, B). However, H&E-stained sections of 
the heart from ISO-injected rats revealed focal areas of 
histopathological lesions primarily limited to the wall 
of the LV as evidenced by degeneration and necrosis of 
cardiomyocytes, inflammatory cell infiltration, cardiac 
interstitial fibrosis (Fig. 1C) and an increase in the thick-
ness of LV wall. Simultaneous administration of SIM with 
ISO injection markedly decreased the histopathological 
lesions induced by ISO injection alone (Fig. 1D).
Table 3. Serum troponin T levels (pg/mL; mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO + SIM)
Mean ± SEM 7.196 ± 0.341 7.198 ± 0.271 48.750 ± 0.649 25.784 ± 0.654
P1 1.000 0.000* 0.000*
P2 1.000 0.000* 0.000*
P3 0.000* 0.000* 0.000* 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
Table 4. Serum creatine phosphokinase-MB levels (U/L; mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO + SIM)
Mean ± SEM 33.548 ± 0.733 33.460 ± 0.888 195.432 ± 0.548 119.806 ± 0.748
P1 1.000 0.000* 0.000*
P2 1.000 0.000* 0.000*
P3 0.000* 0.000* 0.000*
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
Table 5. Serum tumour necrosis factor-alpha levels (pg/mL; mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO + SIM)
Mean ± SEM 7.012 ± 0.477 6.900 ± 0.341 34.888 ± 2.160 16.394 ± 0.606
P1 1.000 0.000* 0.000*
P2 1.000 0.000* 0.000*
P3 0.000* 0.000* 0.000* 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
Table 6. Serum interleukin-6 levels (pg/mL; mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO/SIM)
Mean ± SEM 7.778 ± 0.351 7.636 ± 0.431 34.336 ± 0.762 13.332 ± 0.558
P1 1.000 0.000* 0.000*
P2 1.000 0.000* 0.000*
P3 0.000* 0.000* 0.000* 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
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With Masson’s trichrome stain, mid-ventricular cross 
sections of the heart from control rats and rats treated with 
SIM alone demonstrated normal histological appearance 
and normal collagen architecture with sparsely deposited 
collagen among the cardiomyocytes (Fig. 2A, B). However, 
ISO injection induced a significant increase of the inter-
stitial collagen network in the myocardium (Fig. 2C). On 
the other hand, co-administration of SIM in ISO-injected 
rats significantly reduced the interstitial collagen fibrosis 
(Table 7) as expressed by small patches of fibrosis (Fig. 2D).
Figure 1. Heart sections stained with haematoxylin and eosin. From control rat (A), and from SIM group (B) showing normal architecture;  
C. From ISO group showing extensive necrosis of numerous cardiomyocytes (arrow) and inflammatory cell infiltration (asterisk); D. From ISO/SIM 
group showing marked reduction of histopathological lesions. Scale bars = 100 μm.
Figure 2. Heart sections stained with Masson’s trichrome. From control rat (A), and from SIM group (B) showing scanty fibres of collagen 
type I; C. From ISO group showing extensive deposition of collagen type I fibres (asterisks); D. From ISO/SIM group showing small patches  
of collagen type I fibres (arrows). Scale bars = 200 μm.
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Immunohistochemical study
Immunohistochemical staining of mid-ventricular 
cross sections of the heart from both control rats 
and rats treated with SIM alone with anti-collagen 
III antibody showed sparse deposition of collagen 
type III fibres in-between cardiomyocytes (Fig. 3A, B). 
ISO injection induced significant deposition of im-
munopositive collagen type III fibres extracellularly 
especially in areas with histopathological lesions 
(Fig. 3C). Co-administration of SIM with ISO induced 
significant reduction of deposition of immunopositive 
collagen type III fibres (Table 8, Fig. 3D).
To assess the myocardial expression of iNOS stain-
ing in the different groups, immunohistochemical 
staining of mid-ventricular sections of the heart with 
anti-iNOS antibody was performed. The immunostain-
Table 7. Area per cent of fibrosis as detected by Masson’s trichrome (mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO/SIM)
Mean ± SEM 1.810 ± 0.250 2.060 ± 0.435 21.286 ± 2.015 12.013 ± 3.273
P1 0.957 0.002* 0.112
P2 0.957 0.002* 0.119
P3 0.002* 0.002* 0.166 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
Table 8. Area per cent of collagen-III immunopositivity (mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO/SIM)
Mean ± SEM 0.141 ± 0.025 0.279 ± 0.044 6.177 ± 0.779 2.301 ± 0.231
P1 0.113 0.005* 0.002*
P2 0.113 0.006* 0.003*
P3 0.005* 0.006* 0.021* 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
Figure 3. Heart sections immunostained with anti-collagen III antibody. From control rat (A), and from SIM group (B) showing very weak immuno- 
reactivity; C. From ISO group showing considerable immunoreactivity; D. From ISO/SIM group showing mild immunoreactivity. Scale bars = 50 μm.
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ing for iNOS of these sections was undetectable in 
both control rats and rats treated with SIM alone 
(Fig. 4A, B). On the other hand, ISO injection induced 
significant iNOS immunostaining which was primarily 
localised in sarcoplasm of cardiomyocytes (Fig. 4C) 
with some immunostaining noted within the inflam-
matory cells. Co-administration of SIM with ISO in-
duced depletion of iNOS immunostaining in sarco-
plasm of cardiomyocytes (Table 9, Fig. 4D).
Heart sections immunostained with anti-thiore-
doxin antibody expressed moderate immunoreactivity 
in the sarcoplasm of cardiomyocytes in control rats 
and SIM-treated rats (Fig. 5A, B). ISO injection dem-
onstrated strong immunoreactivity for thioredoxin in 
the sarcoplasm and almost all nuclei of cardiomyo-
cytes (Fig. 5C). Co-administration of SIM with ISO 
induced moderate thioredoxin immunoreactivity in 
the sarcoplasm of cardiomyocytes (Table 10, Fig. 5D).
dIScuSSION
Intraperitoneal administration of ISO for 7 days in 
adult male rats produced cardiac hypertrophy, increased 
HW/BW ratio, and fibrosis as evidenced by increased 
expression of collagen types I and III. These histopatho-
logical changes were associated with significant in-
crease in serum levels of both cardiac injury markers, 
namely troponin-T and CPK-MB, and pro-inflammatory 
biomarkers, namely TNF-a and IL-6. Also, immunohisto-
chemistry demonstrated increased iNOS and thioredoxin 
immunoreactivity in cardiomyocytes in ISO-injected rats. 
Co-administration of SIM markedly attenuated the ISO-
-induced histopathological alterations. The increased 
immunoexpression of iNOS in cardiomyocytes in ISO-
-injected rats and the marked diminution observed in 
rats simultaneously treated with SIM supports the key 
role of inhibiting iNOS in attenuating the deleterious 
cardiac effects of ISO injection.
Table 9. Area per cent of inducible nitric oxide synthase immunopositivity (mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO/SIM)
Mean ± SEM 22.477 ± 2.101 19.379 ± 1.706 66.653 ± 3.220 34.741 ± 1.410
P1 1.000 0.000* 0.007*
P2 1.000 0.000* 0.001*
P3 0.000* 0.000* 0.000*
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
Figure 4. Heart sections immunostained with anti-iNOS antibody. From control rat (A), and from SIM group (B) showing weak immunoreac-
tivity; C. From ISO group showing strong immunoreactivity; D. From ISO/SIM group showing weak immunoreactivity. Scale bars = 50 μm.
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Previous study had shown that repeated ISO adminis-
tration affords a simple non-invasive means for inducing 
myocardial injury and diastolic dysfunction with a low 
incidence of morality [7]. It was proved that a single 
injection of ISO results in a rapid, marked increase in myo-
cardial necrosis in rats [42]. Another study demonstrated 
that the extent of myocardial lesions in rat heart could be 
increased with repeated ISO injections [53].
A significant increase of HW/BW ratio induced by 
ISO injection as compared with control rats is consid-
ered as a sensitive indicator of cardiac hypertrophy [15, 
58, 60]. Co-administration of SIM significantly reduced 
HW and HW/BW ratio in ISO-injected rats. Previous 
studies showed that chronic administration of ISO 
produced LVH [9, 28, 45, 52] and increased ventricular 
collagen content [4]. In this regard, experimental data 
are accumulating, suggesting that the release of super-
oxide (O2
–) induces cardiomyocyte hypertrophy [51].
Determination of collagen type I by Masson’s 
trichrome and collagen type III by immunohisto-
chemical staining suggested marked increase of 
collagen content in the LV of ISO-injected rats rela-
tive to controls. Increased collagen deposition in the 
ventricular extracellular matrix is considered to be 
a sensitive indicator of fibrosis development [11]. 
A previous study in rats proved that expression of 
collagen types I and III mRNA increased after ISO ad-
ministration and extracellular matrix transcripts are 
increased in the LV with ISO administration [5, 34]. 
Similarly, other studies [1, 12, 24] indicated that 
collagen volume fraction of the hypertrophied LV was 
significantly increased as a result of experimental 
hypertension.
Isoproterenol-injected rats showed elevated serum 
levels of TNF-a and IL-6. It has been proposed that ROS 
and pro-inflammatory cytokines are playing a critical 
Figure 5. Heart sections immunostained with anti-thioredoxin antibody. From control rat (A), and from SIM group (B) showing moderate immuno- 
reactivity; C. From ISO group showing strong immunoreactivity; D. From ISO/SIM group showing moderate immunoreactivity. Scale bars = 50 μm.
Table 10. Area per cent of thioredoxin immunopositivity (mean ± standard error of the mean [SEM]) in the studied groups
Group I (Control) Group II (SIM) Group III (ISO) Group IV (ISO/SIM)
Mean ± SEM 51.386 ± 3.337 50.927 ± 3.330 78.961 ± 1.417 66.452 ± 2.628
P1 1.000 0.000* 0.012*
P2 1.000 0.000* 0.010*
P3 0.000* 0.000* 0.045* 
P1 vs. group I; P2 vs. group II; P3 vs. group III; *significant difference (p ≤ 0.05)
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role in LV remodelling. Previous studies have showed 
that b-adrenergic stimulation with ISO-induced car-
diac expression of proinflammatory cytokines such as 
TNF-a and IL-6 [33, 37] was associated with increased 
ROS production and imbalance between nitric acid 
and superoxide anion and these changes could con-
tribute to the structural and functional alterations 
observed [33]. Choudhary et al. [9] stated that ISO 
administration resulted not only in cardiac hyper-
trophy and apoptosis, but also increased oxidative 
stress in ventricular tissue as evidenced by increased 
ROS contents.
Increased expression of iNOS in cytosol of cardio-
myocytes induced by ISO administration was dem-
onstrated. It was proved that ISO administration in-
creased iNOS producing greater amounts of NO [27, 
30]. iNOS is expressed at low levels in cytosol of normal 
cardiomyocytes but could be induced in response to 
several stimuli such as tissue injury, inflammation, cy-
tokines, and growth factors as well as cardiovascular 
disease [10, 31, 49, 61]. Overexpression of iNOS causes 
cardiomyopathy, heart block, and sudden death [36]. 
The detrimental cardiac effects of iNOS have been 
documented by many other investigators [10, 20]. The 
produced NO reacts with superoxide anion (O2
–) to 
form the highly reactive oxidant peroxynitrite (ONOO–) 
[54]. Peroxynitrite can nitrate proteins, which can lead 
to protein dysfunction [54]. Beckman and Koppenol 
[3] stated that the detrimental effects of peroxynitrite 
include oxidation of lipids, nitration of protein, oxida-
tion of free protein-associated thiols and stimulation 
of apoptosis. Another study demonstrated that per-
oxynitrite is a major contributor to cytokine-induced 
myocardial dysfunction [14]. iNOS is also capable of 
generating O2
– independent of NO production [59]. 
O2
– can also dismutate, yielding hydrogen peroxide, 
which can be reduced to highly reactive hydrogen 
radicals. These preoxidants promote lipid peroxidation, 
damaging the heart and blood vessels [36, 55]. Song 
et al. [47] have demonstrated that iNOS expression 
induces apoptosis in cardiomyocytes.
Co-treatment with SIM effectively attenuated 
the ISO-induced cardiac changes including cardiac 
hypertrophy, fibrosis, inflammation, and oxidative 
stress in adult male rats. SIM effectively prevented the 
hypertrophic growth as evidenced by the normal level 
of HW/BW ratio in the SIM co-treated rats compared 
with controls. In accordance, previous studies indi-
cated that treatment with SIM markedly attenuated 
the myocardial hypertrophy of pressure-overloaded 
hearts [22, 38, 51]. This could be attributed to the 
antioxidant property of SIM [51] as evidenced by the 
marked depletion of iNOS in cardiomyocytes.
Heart sections from ISO-injected rats showed 
a significant increase in the mean area per cent of 
strong immunoreaction for thioredoxin compared 
to control rats. It has been reported that enhanced 
thioredoxin expression may be induced by ROS pro-
duced by infiltrating inflammatory cells in acute 
myocarditis [2]. Administration of SIM significantly 
reduced ISO-induced thioredoxin expression. Thus, 
the observed cardioprotective effect of SIM was prob-
ably attributed to the presence of antioxidant and 
anti-inflammatory properties.
Clinical implications
The present study supports the cardioprotective 
role of SIM co-administration against ISO-induced 
LVH through inhibition of iNOS expression as well 
as attenuation of pro-fibrotic and pro-inflammatory 
cytokines, namely TNF-a and IL-6. Also, data concern-
ing the anti-hypertrophic signalling pathways will 
allow the evolution of new approaches for therapy 
of pathological LVH.
Limitations of the study
Microscopic examination of heart sections is con-
sidered the most reliable method for detecting myo-
cardial fibrosis. However, the usage of non-invasive 
methods to demonstrate the presence of myocardial 
fibrosis in rats with spontaneous hypertension and in 
patients with essential hypertension would be highly 
beneficial. In this aspect, the present study did not 
apply a biochemical assessment of fibrillar collagen 
synthesis and degradation. Also, this study did not 
assess the changes in expression of other types of 
NOS including both eNOS and nNOS.
cONcluSIONS
The present results demonstrated that cardiac 
hypertrophy, fibrosis, inflammation, and oxidation 
produced by 7 days of ISO injections could be sub-
stantially attenuated by SIM co-administration. These 
results are also supported by the detected alterations 
in the immunostaining of iNOS in cardiomyocytes 
which was increased by ISO injection and depleted 
by SIM co-treatment. Deletion of iNOS reduces ROS 
production and oxidative stress, which may be re-
sponsible for the beneficial cardiac effect observed 
by SIM co-treatment. 
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